You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205231 - 205240 of 207712 results
  1. Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome

    SBC: CARTESIAN THERAPEUTICS INC            Topic: NHLBI

    ABSTRACT This application is to support a clinical trial of the first mRNA engineered cell therapy for Acute Respiratory Distress Syndrome (ARDS), including ARDS caused by COVID-19. The FDA has already reviewed the IND application and determined that the study may proceed. ARDS is a severe inflammatory respiratory failure that kills an estimated 80,000 Americans each year. 80% of ARDS patients req ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Development of synthetic sphingolipids for prostate cancer therapy

    SBC: SIEGE PHARMACEUTICALS, INC.            Topic: 102

    PROJECT SUMMARY The objective of this project is to develop the synthetic sphingolipid SGE-893 (893) into an FDA-approved cancer therapy, with the ultimate goal of reducing mortality and morbidity rates in end-stage, drug-resistant prostate cancer. 893 shows promising pharmacological characteristics and potent anti-cancer activity in pre-clinical models while sparing normal tissues. 893 and relate ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Secure Open Architecture Open System Technologies for Tactical Networks

    SBC: PROGENY SYSTEMS, LLC            Topic: N093196

    The goal of this SBIR is to develop technologies that will segregate data of various security classification levels using approved hardware and software techniques and simplify data access and usage for the sailor. This effort is designed to increase the productivity of the user by removing or automating the barriers currently involved with accessing data at different classification levels simulta ...

    SBIR Phase II 2011 Department of DefenseNavy
  4. Improving diagnostic sensitivity for difficult-to-lyse microbial samples with nanodroplet technology

    SBC: Triangle Biotechnology, Inc.            Topic: NIAID

    Abstract Infectious diseases are a leading cause of global morbidity and mortality, accounting for 29% of worldwide deaths. Next-generation sequencing (NGS) is a useful tool in pathogen detection, strain identification, and drug susceptibility testing (among other applications). A primary issue for NGS for rapid pathogen genomic analysis is that raw patient samples typically have a low bacterial l ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Low-Cost Laser Diodes for Navy Applications

    SBC: QUINTESSENCE PHOTONICS CORP.            Topic: N02142

    OBJECTIVES OF THIS PHASE Very low cost, kilowatt class high brightness, high efficiency and high operating temperature fiber laser pump modules are enabling technologies for battlefield laser weapons. Required characteristics of these fiber laser pump modules include: • Fabrication cost in the range of $1 per watt • Pump powers to 1.5 kW • Fiber core diameters as low as 200 μm • Rugg ...

    SBIR Phase II 2007 Department of DefenseNavy
  6. A reagent kit for spatial transcriptomic analysis

    SBC: ATLAS BIO, INC.            Topic: 172

    Project Summary Recent advances in massively parallel single cell genomic techniques have enabled researchers to study genomic and gene expression in high resolution. However, these techniques do not preserve spatial context of individual cells within the tissue and can bias representation of various cell types due to cell dissociation that is required before application of the techniques. Commerc ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical performance of hemodynamics-based non-invasive device for skin cancer testing

    SBC: Veriskin, Inc.            Topic: 102

    Skin cancer is the most common form of cancer in the US, accounting for just under half of all diagnosed cancers (5+ million diagnoses), 27,000+ deaths each year and the annual treatment costs of over $8.1 billion. The early diagnosis of skin cancer has significant impact on patient outcomes and health care costs but remains highly subjective and requires highly specialized training while existing ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. AUTOMATED DEIDENTIFICATION OF PATHOLOGY AND RADIOLOGY DATA

    SBC: IMPACT BUSINESS INFORMATION SOLUTIONS, INC.            Topic: 427

    The overall project objective is to optimize and automate the detection and redaction of PHI in radiology data (DICOM) and pathology data (Whole Slide Imaging - WSI) – both header metadata and “burned in” pixel data – thereby minimizing the need for human-in-the-loop review/manual redaction and maximizing deidentified data throughput. Impact Business Information Solutions, Inc (IBIS) has e ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. A Bullet Proof vascular graft to prevent dialysis access cannulation injury

    SBC: Innavasc Medical, Inc.            Topic: 400

    PROJECT SUMMARY End Stage Renal DiseaseESRDis a complex disease that involves total and permanent kidney failure that affects moreindividuals in the United States aloneHemodialysis is a life sustaining therapy for patients suffering from renal failure that requires that blood be withdrawn and cycled through a dialysis machine that performs the function of the failed kidneysThis process must be rep ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Improving lung cancer surgery with an intraoperative, tumor-targeted, activatable fluorescent imaging agent

    SBC: Vergent Bioscience, Inc.            Topic: 102

    PROJECT SUMMARY/ABSTRACT More than 228,000 people in the United States will receive a lung cancer diagnosis this year. Only 14%-49% of early-stage patients survive at least 5 years after their diagnosis, and the survival rates fall below 5% for patients with advanced-stage IIIB or IV. Tumor recurrence after resection is a critical factor influencing these poor prognoses. If any cancerous tissue is ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government